ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A highlight strong backlogs across key sectors, positive revenue guidance, and strategic investments in growth areas. Despite some restructuring costs, the company is focused on margin expansion and capital efficiency. The Q&A reveals confidence in future growth, particularly in Life Sciences and nuclear segments, and potential M&A activities. The strategic plan and strong working capital management further support a positive outlook. Given the market cap, these factors suggest a stock price movement in the 2% to 8% range over the next two weeks.
Key Financial Performance
Full Year Revenue and Adjusted Earnings from Operations Grew by approximately 11% year-over-year, reflecting solid execution across the platform and delivery of innovative solutions to the global customer base.
Q4 Adjusted Revenues Increased by 3.2% year-over-year to $744 million, including organic growth of 1.5% and a 1.7% benefit from foreign exchange translation.
Order Bookings Decreased by 18.4% year-over-year to $704 million, due to the presence of large project awards in consumer products in the prior year.
Gross Margin Increased by 36 basis points year-over-year to 29.4% of adjusted revenues, driven by a higher contribution from higher-margin services and spare parts.
Energy Backlog Increased by approximately 40% year-over-year, driven by nuclear refurbishment, life extension, and new build programs.
Adjusted Earnings from Operations (Q4) Increased by 3.4% year-over-year to $76.8 million, primarily due to higher adjusted revenues, partially offset by increased SG&A costs.
SG&A Expenses Increased by $5.6 million year-over-year to $139.5 million, mainly due to foreign exchange translation and higher professional fees.
Cash Flows from Operating Activities (Q4) Reported at $149.5 million, reflecting improvement in working capital management and transportation reorganization impacts.
Net Debt to Adjusted EBITDA Ratio Ended Q4 at 2.8x, marking a fourth consecutive quarter of improvement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Digital Twin Offering: Evolving the digital twin offering to support customers on a continuous basis, moving beyond individual project execution.
Flex-Line Platform: Introduced Flex-Line, a sterile pharmaceutical production platform integrating key manufacturing steps to accelerate market entry and reduce process complexity.
Life Sciences: Strong demand with a healthy backlog and diversified funnel, including radiopharma and GLP-1 auto-injector equipment.
Food and Beverage: Expanding into adjacent packaging and produce categories to broaden revenue base and build resilience.
Energy: Backlog increased by 40% year-on-year, driven by nuclear refurbishment, life extension, and new build programs.
Consumer Products: Stable funnel activity supported by automation, efficiency, and fulfillment capabilities.
Transportation Operations Reorganization: Consolidating divisions and rationalizing operational footprint, moving away from large-scale automotive projects to focus on niche industrial applications.
Aftermarket Business Integration: Integrated aftermarket businesses into operating units to improve margins and revenue predictability.
Working Capital Management: Improved non-cash working capital as a percentage of revenues to 12.1%, marking three consecutive quarters of improvement.
Capital Allocation: Focused on deploying capital within a framework to enhance margin profile, improve aftermarket mix, and strengthen technical capabilities.
Portfolio Evaluation: Continuing to evaluate portfolio based on strategic focus areas and market dynamics to align with goals of margin improvement and cash flow efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Order Bookings Decline: Order bookings were down 18.4% compared to Q4 last year, reflecting a decline in large project awards in consumer products.
Transportation Reorganization: The company is repositioning its transportation operations, consolidating divisions, and rationalizing its operational footprint. This includes removing dilutive revenues of approximately $50 million and incurring restructuring charges.
Restructuring Costs: The company incurred $28.3 million in costs related to reorganization activities in Q4 and expects additional restructuring costs of $5 million to $10 million in fiscal '27.
Revenue Growth Challenges: Modest revenue growth is expected for fiscal '27, with a step-down in transportation revenues and a more normalized backlog in Life Sciences.
Macroeconomic and Geopolitical Uncertainty: The macro environment remains fluid amid geopolitical and trade uncertainty, which could impact operations and financial performance.
SG&A Cost Increases: SG&A expenses increased by $5.6 million in Q4, driven by foreign exchange translation and higher professional fees.
Capital Allocation Risks: The company plans to pursue larger transactions as financial flexibility increases, which could temporarily raise leverage above the target range of 2 to 3x.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Modest revenue growth expected for fiscal '27, with Q1 revenues projected between $700 million to $740 million. Transportation revenues will decrease due to the shift away from large-scale automotive projects.
Margin Expansion: Adjusted earnings from operations margins are expected to improve by 50 to 75 basis points over fiscal '26 on a full-year basis, with a long-term target of 15%.
Life Sciences Outlook: Strong demand with a $1.1 billion backlog. Growth driven by radiopharma and broader applications such as mail-order pharmacy, automated visual inspection, and lab automation. Introduction of Flex-Line platform to accelerate market entry and reduce complexity.
Energy Sector Growth: Backlog increased by 40% year-on-year, driven by nuclear refurbishment, life extension, and new build programs. Service opportunities expected to grow as programs advance. Active engagement with small modular reactor developers.
Food and Beverage Sector: Strong funnel in core processing markets, with plans to expand into adjacent packaging and produce categories to build resilience against customer capital spending timing.
Capital Allocation: Focus on deploying capital within the framework, with potential for larger transactions as financial flexibility increases. Emphasis on acquisitions that enhance margins, service mix, and technical capabilities.
Restructuring and Reorganization: Transportation operations are being repositioned, with $5 million to $10 million in restructuring costs expected in fiscal '27. Sale of three facilities planned to fund reorganization activities.
Capital Expenditures: CapEx and intangible investments for fiscal '27 expected to range between $70 million and $90 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about bookings in fiscal '27 across the segments, specifically Life Sciences?
A:Life Sciences continues to remain strong with areas of growth, including radiopharma. There are moderations in timing in certain submarkets, but the diversification within the space is positive. The company aims to execute on its backlog and focus on growth areas throughout the year.
Q:Should we still think about growth in the Life Science backlog over the coming year despite moderation in the GLP-1 portion?
A:The goal is to achieve growth in the Life Science backlog. The company entered fiscal '26 with a strong backlog from GLP-1 orders and has seen an uptick in radiopharma backlog, along with other areas of focus within the portfolio.
Q:Could we see M&A while restructuring activity is ongoing, or would restructuring need to be completed first?
A:M&A and restructuring are independent activities. Restructuring focuses on markets that do not fit the long-term profile, while M&A is about future positioning in technology, customer growth, or regional growth. Both can occur simultaneously.
Q:What are the biggest levers contributing to improving capital efficiency metrics?
A:The focus is on margin expansion, working capital management, and asset efficiency, including return on fixed assets and ROI of internal investments. Both areas are being driven simultaneously for improved capital efficiency.
Q:What are the trends impacting the lab equipment space and ATS specifics?
A:The trends are primarily market-driven, including regulatory shifts and budgeting priority changes by national labs or large customers. Despite short-term risks, ATS is confident in its positioning in the lab equipment space, focusing on margin expansion and aftermarket development.
Q:Could deepening nuclear supply chain expertise be a vertical for capital deployment?
A:Yes, the nuclear segment, including traditional CANDU reactors and SMR categories, is a potential area for capital deployment. The focus would be on extending technology or service positions and addressing geographic priorities in markets like the U.S. or U.K.
Q:Where did recurring revenues finish as a percentage of fiscal 2026 revenue, and what initiatives are underway to increase this in fiscal 2027?
A:Recurring revenues were around one-third of the business in fiscal 2026. Initiatives to increase this include service strategies for general management teams, deployment of ABM tools, and investments in digital technologies like digital twin and remote diagnostics.
Q:How much of the 50 to 75 bps of expected margin improvement in fiscal '27 is related to the transportation reorganization?
A:Some of the margin improvement is related to the transportation reorganization, but other levers include integrating services into businesses, operational improvements, and investments in innovation. The goal is to actively manage the portfolio for growth and margin expansion.
Q:Is the full-year revenue guidepost for modest growth gross or net of the transportation headwind?
A:The modest growth guide is inclusive of the step-down in transportation revenues.
Q:How does the modest growth guide for fiscal '27 correspond to the growth rates of end markets?
A:The moderation in growth is primarily timing-related and not indicative of a change in the long-term view of the markets served. The goal remains to outpace broader automation markets, supported by strong tailwinds.
Q:Do you have visibility on when programs will flow through, given the timing reset?
A:The pipeline is strong and diverse, particularly in Life Sciences. While there is some lumpiness in execution, there is no indication of market softening. Timing of large orders affects near-term revenue modestly.
Q:What drove the strong working capital efficiency performance this quarter, and what is the investment rate expectation for this year?
A:The strong performance was due to timing differences in payments and disciplined working capital management. The goal is to maintain working capital efficiency below 15% over time.
Q:What is the update on the auto-injector opportunity related to GLP-1 and other applications?
A:Auto-injector work remains in the backlog but has moderated as expected. The market for auto-injectors is expected to grow long-term, driven by trials for cardiovascular, autoimmune, and neurological therapies.
Q:What type of multiples are seen for private companies versus public peers, and can ATS acquire at or below its current multiple?
A:Valuations vary widely depending on factors like scale, region, and performance. ATS can acquire at or below its current multiple but focuses on value creation and return on capital.
Q:Is there a target ROIC for potential acquisitions?
A:The target is greater than the cost of capital within a 3-plus year horizon. Competing ideas for capital are evaluated based on their ROIC.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical details on the percentage of margin improvement directly attributable to the transportation reorganization and the exact timing of program flows through the pipeline. Additionally, while they discussed the lumpiness in the auto-injector market and the broad spectrum of acquisition multiples, they did not provide precise figures or ranges for these aspects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATS cash
ATS end
Beverage funnel
Cybulski Interim
Demand use
Energy backlog
Flex Line
Life Sciences
Line production
Officer Cybulski
Products order
Radiopharma momentum
Sciences demand
Sciences funnel
Wright Chief
ability demand
accountability strength
action
aftermarket
backlog funnel
base
cash generation
conviction
core
engineering
equipment
expertise
leader
life cycle
life extension
market opportunity
opportunity term
order booking
profile
refurbishment life
revenue order
scale
type
visibility
ATS Transcript
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
Positive5-28
The earnings call summary and Q&A highlight strong backlogs across key sectors, positive revenue guidance, and strategic investments in growth areas. Despite some restructuring costs, the company is focused on margin expansion and capital efficiency. The Q&A reveals confidence in future growth, particularly in Life Sciences and nuclear segments, and potential M&A activities. The strategic plan and strong working capital management further support a positive outlook. Given the market cap, these factors suggest a stock price movement in the 2% to 8% range over the next two weeks.
ATS Corporation (ATS:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call presents a mixed picture. While there is optimism about growth in Life Sciences and nuclear segments, and a strong order backlog, the decrease in gross margin and increased SG&A expenses are concerns. The Q&A reveals cautious optimism but lacks specific guidance, which may cause uncertainty. Given the market cap of $3.18 billion, the stock is likely to have a muted reaction, resulting in a neutral sentiment.
ATS Corporation (ATS:CA) Q2 2026 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong financial performance, with a solid order backlog and promising growth in segments like Life Sciences and Energy. Despite some uncertainties, management provided optimistic guidance, focusing on margin expansion and strategic initiatives. The stock is likely to experience a positive movement, considering the company's market cap and the absence of significant negative factors.
ATS Corporation (ATS) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call presented a strong backlog, positive integration of acquisitions, and favorable market conditions for automation. Management's optimistic guidance on margin improvements and leverage targets, along with strategic diversification efforts, indicate a positive outlook. The Q&A reinforced this sentiment, revealing minimal negative impact from external pressures and ongoing M&A activity. The market cap suggests a moderate reaction, leading to a 'Positive' stock price prediction over the next two weeks.
ATS Slides
ATS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
